Loading clinical trials...
Loading clinical trials...
This study is to evaluate the pharmacokinetics and safety of 800 mg of LDE225 in subjects with impaired hepatic function and healthy subjects with normal hepatic function.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT07055412 · Pharmacokinetic Differences, Y-3, and more
NCT02586194 · Patients With Impaired Hepatic Function
NCT00398424 · Impaired Hepatic Function
NCT04823702 · Impaired Hepatic Function
NCT04136444 · Healthy Study Participants, Impaired Hepatic Function
University of Miami Div. of Clinical Pharmacology
Miami, Florida
Novartis Investigative Site
Brussels
Novartis Investigative Site
Sofia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions